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Abstract
Introduction: Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive
nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections
caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We
conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill
patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics.
Methods: The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April
2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for
more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides,
glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.
Results: The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or
with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and
had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI,
but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final
logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI
during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in
the 222 patients treated with CMS alone or NAs alone.
Conclusions: In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more
than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of
AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by
the SAPS II score.
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Introduction
Throughout the world, Acinetobacter baumannii, Pseu-
domonas aeruginosa and Klebsiella pneumonia have
emerged as major causes of nosocomial infections [1],
particularly in patients who are critically ill and/or
immunocompromised. Concern has been raised by
reports of a stepwise trend towards extensive drug-resis-
tance in these organisms [1]. Infections caused by exten-
sively drug-resistant (XDR) bacterial strains are
associated with high mortality rates, especially in inten-
sive care units (ICUs), where outbreaks are extremely
difficult to control. The limited therapeutic options in
these cases often lead clinicians to resort to salvage
therapy with colistin methanesulfonate (CMS). This
older polymyxin antibiotic, which is converted in vivo to
colistin [2], was widely abandoned in the 1970s because
of its unfavorable pharmacokinetic properties and fre-
quent adverse effects, particularly nephrotoxicity.
The “modern polymyxin era” [3], which began in the
late 1990s, is characterized by a variety of dosing sche-
dules, but to date there is still a dearth of information
on the clinical pharmacokinetics of CMS and colistin in
critically ill patients [4]. Higher doses appear to be bene-
ficial in these cases [5], but it is unclear whether the
improved efficacy comes at a cost of increased toxicity.
The aim of this retrospective cohort study was to evalu-
ate the potential risk factors for acute kidney injury
(AKI), as defined by the RIFLE (Risk of renal dysfunc-
tion, Injury to the kidney, Failure of kidney function,
Loss of kidney function, End-stage kidney disease) clas-
sification system [6], in severely ill ICU patients without
pre-existing renal disease who received high-dose intra-
venous CMS therapy for more than seven days.
Materials and methods
This study was conducted in two large tertiary-care
teaching hospitals in Rome, Italy (Policlinico Umberto I
and the Policlinico Gemelli), and it involved retrospec-
tive analysis of prospectively collected data. Cases were
identified through searches of the ICU patient databases,
and data were collected from the patients’ electronic
medical records.
The study cohort consisted of adults (≥18 years) con-
secutively admitted to the general ICUs of the partici-
pating facilities between April 2009 and June 2011
(Figure 1). Inclusion criteria were: 1) no evidence on
ICU admission - as well as at protocol admission - of
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Figure 1 Study design. AKI, acute kidney injury (defined according to RIFLE criteria); CMS, colistin methanesulfonate sodium; NAs, nephrotoxic
antibiotics (aminoglycosides, glycopeptides); Pts, patients.
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filtration rate (GFR) relative to serum creatinine (SCr)
based on age, race and sex formula assuming a glomeru-
lar filtration rate of 75 mL/min/1.73 m2, as recom-
mended by the Acute Dialysis Quality Initiative (ADQI)
Working Group [6]. Most ICU patients, in fact, have not
a prior measure of renal function and a simplified modifi-
cation of diet in renal disease (MDRD) formula provides
a simple and precise estimation of baseline GFR and SCr
2) onset >48 h after ICU admission of an XDR bacterial
infection treated for seven or more days with intravenous
(iv) CMS and/or other nephrotoxic antimicrobial agents
(NAs, that is, aminoglycosides and glycopeptides).
Extensively drug-resistant (XDR) was defined as non-
susceptibility to at least one agent in all but two or fewer
antimicrobial categories (that is, bacterial isolates remain
susceptible to only one or two categories) [7]. Patients
were excluded if the antibiotic therapy described above
had been started prior to ICU admission.
The primary end point of the study was to evaluate
the potential risk factors for acute kidney injury (AKI)
in severely ill ICU patients without pre-existing renal
disease who received high-dose intravenous CMS ther-
apy with or without other nephrotoxic antimicrobials.
For this purpose, patients were classified daily using
the RIFLE criteria and AKI was defined using the serum
creatinine compared to the baseline value of the SCr
previously obtained from the MDRD equation.
A patient was considered to have AKI when he had an
increase in SCr of at least 50% from baseline (defined as
Risk) or if he doubled the SCr level from the baseline
(defined as Injury) or had a three times increase in SCr
(defined as Failure) [6,8] (Figure 2).
For each patient included in the cohort, electronic hos-
pital charts were reviewed, and the following collected
data were recorded: demographic variables; Simplified
Acute Physiology Score II (SAPS II); presence on admis-
sion of hypertension, diabetes mellitus, and/or congestive
heart failure; reason for ICU admission; length of ICU
stay; type and cause of infection; nephrotoxic drugs and iv
iodate contrast used, immunocompromised status; albu-
min serum level, bilirubin serum level and, for CMS, dura-
tion of therapy and cumulative doses; presence of septic
shock caused by the XDR infection; use of continuous
renal replacement therapy (CRRT) during the ICU stay
and ICU mortality.
Septic shock was diagnosed as a state of acute circula-
tory failure characterized by persistent arterial hypoten-
sion despite adequate fluid resuscitation or by tissue
hypoperfusion in the presence of proven or suspected
infection [9]. Bloodstream infection (BSI) was defined as
at least one positive blood culture for a potential bacter-
ium together with clinical features compatible with sys-
temic inflammatory response syndrome; the clinical
suspicion of pneumonia was based on either clinical cri-
teria (new or progressive radiologic pulmonary infiltrate
together with at least two of the following: temperature
>38°C or <36°C, leukocytosis >12,000/mL or leucopoenia
<4,000/mL, or purulent respiratory secretions) or a sim-
plified Clinical Pulmonary Infectious Score greater than
or equal to six points. The microbiologic evaluation
included the collection of at least one lower respiratory
airway sample by tracheobronchial aspirates, broncho-
scopic or blind bronchoalveolar lavage, within the first
24 hours of the onset of symptoms. Microbiologic confir-
mation of pneumonia was defined by the presence of
at least one potentially pathogenic microorganism in
respiratory samples above predefined thresholds bronch-
oalveolar lavage >104, and sputum or tracheobronchial
aspirates >105 colony-forming units/ml, respectively
[10,11].
CLASS                                                 GFR CRITERIA                                                           URINARY OUTPUT CRITERIA
_______________________________________________________________________________________________________ 
RISK                                     Serum creatinine × 1.5    or  GFR decrease >25%                       <0.5 ml/kg/h × 6 h͒
INJURY                                Serum creatinine × 2    or     GFR decrease >50%                       <0.5 ml/kg/h × 12 h
FAILURE                              Serum creatinine × 3,  or GFR decrease >75%                            <0.3 ml/kg/h × 24 h, or anuria 12 h
                                             Serum creatiniQHPJGZLWKDQDFXWHULVH!0.5 mg/dl               
LOSS                                   Persistent acute renal failure = complete loss of kidney function >4 weeks
͒ END-STAGE                   End-stage kidney disease >3 months
KIDNEY DISEASE
Figure 2 RIFLE classification. Patients are classified on serum creatinine or urinary output, or both, the worst parameters are used. Glomerular
filtration rate (GFR) criteria are calculated as an increase of serum creatinine above the baseline serum creatinine level. When the baseline serum
creatinine is unknown and there is no past history of chronic kidney disease, serum creatinine is calculated using the Modification of Diet in Renal
Disease formula for assessment of kidney function assuming a GFR of 75 ml/min/1.73 m2. RIFLE, Risk Injury-Failure-Loss-End-stage kidney disease.
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This study was approved by our institutional review
board that waived the need for informed consent, due
to the retrospective design of this study.
Statistical analysis
MedCalc software, version 12.1.0 (MedCalc® Software v
12.2.1, MariaKerke, Belgium) was used for all statistical
analyses. Differences between groups were assessed with
the Mann-Whitney test and results given as medians
and interquartile ranges (IQR). The Kolmogorov-Smir-
nov test was used to assess variable distribution. Catego-
rical variables, presented as proportions, were analyzed
with the chi-square test or Fisher’s exact test, as appro-
priate. P-values of <0.05 were regarded as significant.
Potential risk factors for AKI were identified by means
of univariate analysis with calculation of crude odds
ratios (ORs). Those that emerged from this analysis with
a P-value of <0.2 were candidates for inclusion in the
multivariate model. The variables included in the final
predictive model were selected with a stepwise proce-
dure, and the accuracy of the model was assessed in
terms of the area under the receiver operating charac-
teristic (ROC) curve.
Results
Between April 2009 and June 2011, 1,474 adult patients
were consecutively admitted to the two participating
ICUs, and 279 (19%) of these met the criteria for inclu-
sion in the study (Figure 1). Their characteristics are
reported in Tables 1 and 2. The NAs patients were
older, had a longer ICU stay and had a higher percen-
tage immunocompromised than the other groups; the
number of NAs patients treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) were statistically signifi-
cant in respect to the CMS group (Table 1).
One hundred thirty-two of the patients received intra-
venous therapy with NAs alone (glycopeptides and ami-
noglycosides). Eight (6%) of these patients received two
nephrotoxic antimicrobials.
The other 147 were treated intravenously with CMS,
alone (CMS group, n = 90) or with one or more NAs
(CMS + NAs group, n = 57). The NAs in the latter
group were vancomycin in 39 cases, vancomycin plus
amikacin in 7, amikacin in 5, gentamicin in 3, and van-
comycin plus gentamicin in 3. In all cases, the infection
was associated with at least one bacterial isolate that
displayed persistent in vitro susceptibility to colistin
only. In the subgroup that was also receiving NAs,
patients also had one or more isolates displaying sus-
ceptibility to the specific NA being administered.
CMS was administered as Colimicina® (UCB Pharma
SpA, Milan, Italy); 1 million UI per vial). All 147
patients received a loading dose of CMS (4 million IU)
followed by a daily dose of 130,000 IU per kilogram of
ideal body weight (IBW) (divided into three doses per
day) [12]. For patients with creatinine clearance of less
than 70 mL/min but more than 30 mL/min one-third of
the normal daily dose twice a day (for example, 6 mil-
lion IU divided into two doses per day for a 70 Kg
patient); with a creatinine clearance <30 mL/min one-
third of the normal daily dose once a day (for example,
3 million IU once a day for a 70 Kg patient); during
CRRT we used one-third of the normal daily dose twice
a day [13,14].
The median length of CMS therapy was 11 days; the
cumulative CMS dose was 93.999.975 IU, and there
were no significant differences between the CMS and
CMS + NA subgroups involving any of these variables
(P = 0.26 and P = 0.37, respectively)
Normogram based on creatinine clearance (CLCr) was
used for calculation of the vancomycin daily dosage
administered by continuous infusion in order to target a
steady state concentration (CSS) at 15 to 20 mg/L [15].
We, therefore, confirm our dosage monitoring the
serum vancomicin concentration. Aminoglycoside were
administered according to one daily dosing schedule of
20 mg/kg/day for Amikacin and 5 mg/kg/day for Genta-
mycin; dosage was confirmed by monitoring the serum
concentration and was adjusted as a function of CLCr.
The target trough (1 µg/mL) was easily achieved using a
once daily dose [16]
A total of 116 (41%) of the patients died while they
were in ICU (Table 1).
One hundred eleven (40%) of the 279 patients devel-
oped AKI during their stay in the ICU. In the NAs group,
10% the AKI cases were classified as Risk, 13% as Injury
and 18% as Failure; in the CMS group, 6% of the cases
were classified as Risk, 7% as Injury and 22% as Failure;
and in the CMS + NAs group, 7% of the AKI cases classi-
fied as Risk, 12% as Injury and 26% as Failure. The med-
ian onset of AKI was 10 days (8 to 15) (25th to 75th) in
the CMS group, 11 days (10 to 12) (25th to 75th) in the
NAs group, 12 days (10 to 21) (25th to 75th) in the CMS
+ NAs group. Compared with the non-AKI subgroup,
those who developed AKI were significantly older and
had significantly higher SAPS II scores. In addition, sep-
tic shock rates and ICU mortality were roughly three
times higher than those in the non-AKI group; in fact, in
the AKI group, the ICU mortality and septic shock rates
were 70% and 74%, respectively (Table 2). The vast
majority of AKI patients had an albumin serum level less
than 2 g/dL (Table 2). The vast majority of the infections
considered in this study were ventilator-associated pneu-
monia (VAP) or catheter-related bloodstream infections
(CRBSIs), and in almost half of all cases (46%), septic
shock was present at infection onset.
We did not find any difference in the incidence of
AKI in respect to the etiology of infections among the
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three groups studied. Nine out of 17 Failure patients
who survived were discharged from ICU as Failure but
without a dialysis prescription; 1 as Injury, 4 as Risk and
3 with a complete recovery of the renal function. Five
out of 7 Injury patients who survived were discharged
from ICU as Injury and 2 as Risk. Five out of 9 Risk
patients who survived were discharged from ICU as Risk
and 4 with a complete recovery of the renal function
(Table 3).
The results of the logistic regression are shown in
Tables 3, 4 and 5. In the complete study population (n =
279), the multivariate analysis showed that SAPS II
scores and the presence of septic shock at infection onset
were independently associated with AKI. The other sig-
nificant variables at the univariate analysis were not
included in the multivariate final logistic model using a
stepwise procedure. A ROC curve analysis was performed
to assess the accuracy of the final regression model show-
ing AUC ± SE = 0.79 ± 0.03 with 95% C.I. 0.74 to 0.84;
Chi Square statistics: P <0.001 (Table 4). In the 147
patients who received CMS (Table 5), the likelihood of
developing AKI was not significantly different in the
CMS and CMS + NA subgroups. In contrast, onset of
AKI was two times more likely in patients with a SAPS II
score ≥43 and six times more likely in those whose infec-
tions had presented with septic shock. A ROC curve
Table 1 ACEI, angiotensin converter enzyme inhibitor; AKI, acute kidney injury as defined per RIFLE criteria; BMI, body
mass index; BSI, bloodstream infection; CMS, colistin methanesulfonate sodium; CRRT, continuous renal replacement
therapy; CVC, central venous catheter; NSAID, nonsteroidal anti-inflammatory drug; Pts, patients; SAPS II, simplified







Age (years) 57 (40 to 69) 54 (39 to 66) 67 (48 to 76) *
Female, n (%) 32 (35) 20 (35) 40 (30)
SAPS II 41 (32 to 54) 44 (30 to 54) 44 (35 to 55)
BMI, Kg/m2 25 (24 to 25) 24 (23.7 to 25) 24 (23 to 27)
ICU length of stay, (days) 28 (17 to 38) 33 (19 to 50) 15 (8 to 31) *
Albumin serum level <2 g/dL, n (%) 14 (15) 9 (16) 18 (14)
Total bilirubin serum level >5 mg/dL n (%) 7 (8) 4 (7) 11 (8)
NSAID n (%) 17 (19) 10 (18) 43 (33) ****
ACEI n (%) 15 (17) 3 (5) 16 (12)
i.v. iodate contrast n (%) 35 (39) 14 (25) 45 (34)
Immunocompromised pts n (%) 13 (14) 8 (14) *** 38 (29) * *
Reason for ICU admission
Sepsis, n (%) 41 (46) 20 (35) 56 (43)
Neurological injury, n (%) 4 (4) 8 (14) 12 (9)
Traumatic injury, n (%) 31 (34) 21 (37) 31 (23)
Cardiovascular injury, n (%) 14 (16) 8 (14) 33 (25)
Comorbidity
Hypertension, n (%) 14 (16) 12 (21) 28 (21)
Diabetes mellitus, n (%) 2 (2) 2 (3.5) 9 (7)
Congestive heart failure, n (%) 3 (3) 2 (3.5) 10 (7.5)
Two or more comorbidities, n (%) 5 (5) 4 (7) 16 (12)
Site of infection
VAP, n (%) 69 (77) 40 (70) 91 (69)
CVC related-BSI, n (%) 18 (20) 13 (23) 31 (23)
Other, n (%) 3 a (3) 4b (7) 10 c (7)
Complications occurring during ICU stay
CRRT, n (%) 13 (14) 14 (24) 29 (22)
AKI, n (%) 31 (34) 26 (45) 54 (41)
Septic shock, n (%) 31 (34) 27 (47) 70 (53)
ICU mortality, n (%) 31 (34) 21 (37) 64 (49)
Other nephrotoxic antimicrobial included aminoglycosides and glycopeptides.
(a) wound infection n = 2, abdominal abscess n = 1. (b) wound infection n = 1, abdominal abscess n = 1, urinary tract infection n = 2. (c) urinary infection n = 4,
abdominal abscess n = 3, wound infection n = 1, meningitis n = 2. Values are given as the median (interquartile range).
* P <0.01 NAs vs CMS and CMS/NAs; **P = 0.01 CMS vs NAs; *** P = 0.04 CMS/NAs vs NAs P = 0.03 ****
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analysis was performed to assess the accuracy of the final
regression model showing AUC ± SE = 0.76 ± 0.04 with
95% CI 0.7 to 0.8; Chi-square statistics P <0.001.
A similar picture emerged when we analyzed the 222
patients who received CMS alone (n = 90) or NAs alone
(n = 132) (Table 6). The only independent predictors of
AKI in this group were SAPS II scores ≥44 and septic
shock at infection onset. A ROC curve analysis was
Table 2 ACEI, angiotensin converter enzyme inhibitor; AKI, acute kidney injury; BSI, bloodstream infection; CMS,
colistin methanesulfate; CVC, central venous catheter; NAs, other nephrotoxic antibiotics (aminoglycosides,
glycopeptides); NSAID, nonsteroidal anti-inflammatory drug; SAPS II, Simplified Acute Physiology Score Two








Age, years b 61 (43 to 74) 58 (39 to 71) 66 (51 to 77) <0.01 *
Female, n (%) 92 (33) 62 (37) 30 (27) 0.09 **
SAPS II score b 44 (32 to 54) 38 (29 to 49) 50 (41 to 56) <0.01 *
Septic shock at infection onset - n (%) 128 (46) 46 (27) 82 (74) <0.01 **
Albumin serum levels <2 g/dL n (%) 38 (14) 15 (9) 23 (21) <0.01 **
Total bilirubin serum levels >5 mg/dL n(%) 19 (7) 8 (5) 11 (10) 0.15 **
NSAID n (%) 70 (25) 48 (28) 22 (20) 0.13 **
ACEI n (%) 34 (12) 16 (10) 18 (16) 0.13 **
Immunocompromised pts n (%) 59 (21) 34 (20) 25 (23) 0.75 **
i.v. iodate contrast n (%) 94 (34) 53 (32) 41 (37) 0.42 **
Reason for ICU admission
Sepsis, n (%) 117 (42) 60 (36) 57 (51) 0.01 **
Neurological disease, n (%) 24 (8) 18 (10) 6 (5) 0.18 **
Trauma, n (%) 83 (30) 62 (37) 21 (19) <0.01 **
Cardiovascular disease, n (%) 55 (20) 28 (17) 27 (24) 0.15 **
Comorbidity
Hypertension, n (%) 54 (20) 27 (16) 27 (24) 0.12**
Diabetes mellitus, (%) 13 (4) 6 (4) 7 (6) 0.44**
Congestive heart failure, n (%) 15 (6) 9 (5) 6 (5) 0.79 **
Two or more comorbidities 25 (9) 11 (6) 14 (13) 0.13 **
Type of infection
VAP, n (%) 200 (72) 118 (70) 82 (74) 0.6 **
CVC related-BSI, n (%) 62 (23) 39 (23) 23 (21) 0.73 **
Other, n (%) 17 (5) 11 (7)c 6 (5) d 0.89 **
Treatment
CMS, n (%) 90 (32) 59 (35) 31 (28) 0.25**
CMS+NAs, n (%) 57 (20) 31 (18) 26 (23) 0.39 **
CMS+ glycopeptides alone e, n (%) 39 (68) 23 (59) 16 (41) 1***
CMS + aminoglicoside alonee, n (%) 8 (14) 5 (62.5) 3 (37.5)
NAs, n (%) 132 (47) 78 (47) 54 (48) 0.8 **
Outcome
Days in ICU b 23 (13 to 37) 22 (13 to 34) 25 (14 to 42) 0.16 *
ICU mortality - n (%) 116 (41) 38 (23) 78 (70) <0.01 **
a Differences between subgroups with and without AKI onset after ICU admission: *Mann-Whitney test; **Chi-squared test, *** Fisher’s exact test
b Values are given as the median (interquartile range).
c wound infection n = 2, abdominal abscess n = 5, urinary tract infection n = 2, meningitis n = 2
d wound infection n = 1, abdominal abscess n = 3, urinary tract infection n = 2
e in this analysis were excluded the patients who received aminoglycoside + glycopeptide ( n = 10) (18%)
Table 3 Outcome at the ICU discharge of AKI patients
AKI during ICU
stay











Risk n = 22 4 5 0 0 12
Injury n = 30 0 2 5 0 21
Failure n = 59 3 4 1 9 45
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performed to assess the accuracy of the final regression
model showing AUC = 0.8 ± 0.03 with 0.75 to 0.86 95%
CI; Chi-square statistics: P <0.01.
These findings indicate that in ICU patients without
pre-existing renal disease who require nephrotoxic anti-
microbial drug therapy for XDR bacterial infections, the
use of CMS - with or without NAs - does not signifi-
cantly increase the risk for AKI over that associated
with NAs therapy alone.
Discussion
The cohort treated with high doses of CMS for nosoco-
mial XDR infections in our study represented approxi-
mately 10% of the entire population admitted to the
general ICUs during the two-year study period. The
overall incidence of AKI in the 279 cases we analyzed
was 40%, and there were no significant differences
among rates observed in the CMS (34%), CMS+NAs
(45%) and NAs subgroups (41%). These data are
consistent with the results of the Nefroint study [8], a
multicenter study conducted in Italian ICUs: in the sub-
group of 133 patients without AKI at ICU admission,
the incidence of AKI was 40% regardless of whether or
not nephrotoxic drugs were administered. A recent
meta-analysis [17] on six controlled studies comparing
colistin vs other antibiotics for treatment of VAP in
patients without cystic fibrosis suggested that colistin
may be as safe as other standard antibiotics used for
these drug-resistant infections. In particular, the nephro-
toxicity rate for colistin was similar to that in the con-
trol group.
Our multivariate analysis revealed that SAPS II scores
≥43 and the presence of septic shock at infection onset
were independently associated with AKI, but high-dose
intravenous CMS therapy for more than seven days was
not a risk factor for development of new onset AKI.
Since CMS’s recent re-emergence as a last-resort
treatment of infections caused by XDR pathogens
Table 4 Logistic regression analysis of factor associated with AKI in the study cohort
Univariate analysis Multivariate analysis
Variables O.R. 95% C.I. P-value O.R. 95% C.I. P-value
Age, years 1.02 1.01 to 1.04 <0.01
SAPS II score 1.04 1.03 to 1.06 <0.01 1.03 1.01 to 1.05 <0.01
Female 0.63 0.37 to 1.06 0.08 0.62 0.34 to 1.14 0.12
Septic shock at infection onset 7.5 4.36 to 12.9 <0.01 5.89 3.35 to 10.35 <0.01
Albumin serum levels <2 g/dL 2.66 1.32 to 5.37 <0.01
Total bilirubin serum levels >5 mg/dL 2.2 0.85 to 5.65 0.1
NSAID 0.62 0.35 to 1.1 0.1
ACEI 1.83 0.89 to 3.78 0.1
i.v. iodate contrast 1.27 0.76 to 2.1 0.35
Immunocompromised status 1.14 0.63 to 2.05 0.64
Causes of ICU admission
Sepsis 1.9 1.17 to 3.1 <0.01 1.74 0.99 - 3.05 0.052
Neurological disease 0.47 0.18 to 1.24 0.13
Trauma 0.4 0.22 to 0.7 <0.01
Cardiovascular disease 1.61 0.89 to 2.9 0.12
Co-morbidities
Hypertension 1.68 0.92 to 3.05 0.09
Diabetes mellitus 1.79 0.58 to 5.47 0.31
Congestive heart failure 1 0.35 to 2.92 0.99
Two or more comorbidities 2.06 0.9 to 4.72 0.08
Type of infection
VAP 1.19 0.7 to 2.05 0.51
CVC related-BSI 0.86 0.48 to 1.55 0.62
Other 0.81 0.29 to 2.27 0.7
Treatment with CMS (vs. NAs) 0.91 0.56 to 1.47 0.7
The variables included in the final predictive model were selected with a stepwise procedure: albumin serum levels <2 g/dL, total bilirubin serum levels >5 mg/
dL, ACE inhibitors, NSAID, age, neurological disease, trauma, cardiovascular disease, hypertension and two or more co-morbidities were variables not included in
the final model. We assessed discrimination of the model with area under the receiver operating curve (AUC ± SE = 0.79 ± 0.03 with 95% C.I. 0.74 to 0.84; Chi
Square statistics: P <0.001).
ACEI, angiotensin converter enzyme inhibitor; AUC, area under the curve; BSI, bloodstream infection; CI, confidence interval; CMS, colistin methanesulfate; CVC,
central venous catheter; NAs, other nephrotoxic antibiotics (aminoglycosides, glycopeptides); NSAID, nonsteroidal anti-inflammatory drug; SAPS II, Simplified
Acute Physiology Score Two (calculated 24 h after ICU admission); VAP, ventilator-associated pneumonia.
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Table 5 Logistic regression analysis of factors associated with AKI in patients who received CMS and CMS/NAs.
Univariate analysis Multivariate analysisb
Variables No. AKI/total (%) O.R. 95% C.I. P-value O.R. 95% C.I. P-value
Age, years a
<55 23/71 (32) 1.00
≥55 34/76 (45) 1.68 0.86-3.31 0.13
Sex
Male 39/95 (41) 1.00
Female 18/52 (34) 0.76 0.37-1.53 0.44
SAPS II a
<43 20/73 (27) 1.00
≥43 37/74 (50) 2.65 1.33-5.27 <0.01 2.26 1.07-4.79 0.03
Septic shock at Infection onset
No 20/89 (22) 1.00
Yes 37/58 (64) 6.1 2.92-12.62 <0.01 5.64 2.66-11.94 <0.01
Treatment with CMS
CMS with NAs 26/57 (45) 1.00
CMS alone 31/90 (34) 0.62 0.31-1.23 0.17
Cumulative CMS dose a,c
<93.999.975 (IU) 33/73 (45) 1.00
≥93.999.975 (IU) 24/74 (32) 0.58 0.29-1.13 0.11 0.61 0.29-1.29 0.19
Duration of CMS therapya
<11 days 30/72 (42) 1.00
≥11 days 27/35 (36) 0.78 0.4-1.53 0.48
The variables included in the final predictive model were selected with a stepwise procedure: age and treatment with CMS were not included in the final model.
a age, SAPS II, duration of CMS therapy, and cumulative CMS dose were dichotomized around median values. b The ROC curve analysis was used to assess the
goodness of the final logistic regression model (AUC ± SE = 0.76 ± 0.04 with 95% CI 0.7 to 0.8; Chi-square statistics P <0.001). c Includes loading dose of 4,000,000 IU.
AKI, acute kidney injury; AUC, area under the curve; CI, confidence interval; CMS, colistin methanesulfate; IBW, ideal body weight; IU, international unit; NAs, nephrotoxic
antibiotics (aminoglycosides, glycopeptides); ROC, receiver operating characteristic; SAPS II, Simplified Acute Physiology Score II (calculated 24 h after ICU admission).
Table 6 Logistic regression analysis of factors associated with AKI in patients who received CMS and NAs
Univariate analysis Multivariate analysisb
Variables No. AKI/total (%) O.R. 95% C.I. P-value O.R. 95% C.I. P-value
Age, years a
<64 36/110 (32) 1.00
≥64 49/112 (43) 1.59 0.92-2.75 0.09
Sex
Male 63/150 (42) 1.00
Female 22/72 (30) 0.6 0.33-1.1 0.1 0.6 0.29-1.2 0.15
SAPS II a
<44 25/109 (22) 1.00
≥44 60/113 (53) 3.8 2.13-6.79 <0.01 2.45 1.17-4.74 <0.01
Septic shock at Infection onset
No 19/121 (15) 1.00
Yes 66/101 (65) 10.12 5.34-19.12 <0.01 8.24 4.26-15.93 <0.01
Treatment with CMS
No 54/132 (41) 1.00
Yes 31/90 (34) 0.75 0.43-1.32 0.33
The variables included in the final predictive model were selected with a stepwise procedure: age was not included in the final model.
a Age, SAPS II were dichotomized around median values.
bThe ROC curve analysis was used to assess the goodness of the final logistic regression model (AUC = 0.8 ± 0.03 with 0.75 to 0.86 95% CI; Chi-square statistics: P <0.01)
AKI, acute kidney injury; AUC, area under the curve; CI, confidence interval; CMS, colistin methanesulfate; NAs, nephrotoxic antibiotics (aminoglycosides,
glycopeptides); ROC, receiver operating characteristic; SAPS II, Simplified Acute Physiology Score Two (calculated 24 h after ICU admission).
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(including Acinetobacter baumanii, Pseudomonas aerugi-
nosa and Klebsiella pneumonia), many authors have
investigated its adverse effects, in particular, its potential
nephrotoxicity. Like aminoglycosides, the polymyxins
cause damage to the kidneys at the level of the proximal
tubules, where both classes of drugs are extensively
reabsorbed via the endocytic receptor protein megalin
[18]. Colistin was originally used in the 1960s to combat
infections caused by gram-negative bacteria, but it was
abandoned in the 1970s because of its reported associa-
tion with high nephrotoxicity rates [13,19] and because
new, apparently less toxic antibiotics (for example, the
aminoglycosides) were becoming available. Several stu-
dies published over the past decade, however, have
demonstrated that CMS is not associated with serious
adverse effects, and although nephrotoxicity incidence
rates varied (0% to 32%) [20-24], they were clearly lower
than those reported in the 1960s and 1970s. The differ-
ences between older and more recent findings have
been attributed to various factors, including the
increased presence of chemical impurities in older colis-
tin preparations, the variable definitions of acute renal
impairment used in the various studies, closer monitor-
ing and, last but not least, the improved maintenance of
patient hydration by today’s physicians [20].
Research endorsed by the Acute Dialysis Quality
Initiative led to the publication of the RIFLE classifica-
tion, with standardized criteria for various degrees of
renal dysfunction [6]. The RIFLE approach can detect
AKI with high sensitivity and high specificity. It can also
be used to predict the prognosis of affected patients,
and it provides a useful framework for comparing the
results of different studies. Two recent studies that used
the RIFLE criteria to investigate colistin-related nephro-
toxicity [25,26] documented high incidences of mild
renal impairment (about 43%) in both cohorts (even
though the two populations differed in terms of illness
severity).
Indeed, in most recent studies, the colistin-treated
populations have been heterogeneous in terms of base-
line illness severity, baseline renal function and treat-
ment variables, including daily doses and duration of
treatment. Daily doses of CMS used in these studies
ranged from 3 million to 11 million IU [21,25,27-30].
To make matters worse, there is also wide variation
involving the type of preparation used, that is, CMS
(where 2 million IUs correspond to 160 mg of the drug)
versus colistin base (where 2 million IUs equals 60 mg).
The importance of universal dosing terminology has
been emphasized by several investigators [19,20].
This antibiotic is being used with increasing frequency
to treat critically ill patients - despite the absence of
clinical guidelines and dosing recommendations for this
particular population. Multi-organ dysfunction and
severe XDR infections can alter the pharmacokinetics of
CMS and colistin in terms of half-life and rates of for-
mation of colistin from CMS [30], and the larger
volumes of distribution present in these critically ill sep-
tic patients can cause a lower concentration of the anti-
biotic [5]. Early and appropriate goal-directed fluid
therapy is fundamental in acute resuscitation of these
critically ill patients; however, it is almost always asso-
ciated with a certain degree of fluid overload, especially
in septic patients, which promotes tissue edema that
could potentially contribute, itself, to progressive organ
dysfunction. Both fluid balance and urine volume are
independent predictors of mortality in adult critically ill
patients with AKI [31].
Plachouras et al. [12] studied the pharmacokinetics of
intravenously administered CMS in critically ill patients
and concluded that a loading dose of at least 9 million
IU of CMS is needed in these cases to produce plasma
concentrations of the drug within the minimum inhibi-
tory concentration (MIC) range indicative of susceptibil-
ity. Failure to achieve such concentrations can lead to
the emergence of resistant strains, and it can also result
in increased mortality.
In light of these findings, we decided to investigate the
nephrotoxicity of high-dose CMS therapy, in terms of
RIFLE-defined AKI, in patients with no AKI at baseline.
Hartzell and collaborators [25] used a similar approach
in a young and otherwise healthy population of patients
on a general medicine ward. The patients had no other
confounding comorbidity, but the mean duration of
CMS therapy was longer than it was in our study. The
authors found a significant association between the
cumulative CMS dose and the risk of nephrotoxicity in
patients receiving CMS for more than 14 days. This
finding contrasts with the results of our logistic regres-
sion analysis, which showed that neither the cumulative
CMS dose nor the duration of treatment was a risk fac-
tor for developing new-onset AKI in severely ill ICU
patients. The median days of CMS treatment of our
patients, however, was lower that than reported by Hart-
zell and collaborators and could probably justify the dis-
cordance with our results as well as the difference in
severity of the two population studied. We agree, never-
theless, that creatinine levels need to be closely moni-
tored in patients receiving prolonged treatment with
CMS.
Pogue et al. [26] reported that CMS nephrotoxicity is
related to the daily dose but not to cumulative exposure.
However, the population they studied was heteroge-
neous in terms of pre-treatment renal function. Further-
more, although illness severity scores were not reported,
their patients were probably not as critically ill as ours.
Only 14% had septic shock, 15% were on vasopressors
and only 62% were being mechanically ventilated. These
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are important differences because, as noted above, the
pharmacokinetics of CMS and colistin are different in
the critically ill [5,29], and in our study a SAPS II score
≥43 was independently associated with AKI. Compari-
son of findings in ICU and non-ICU cohorts is also
complicated by the fact that the former patients are
likely to be more closely monitored and more rapidly
treated than those being cared for on general wards.
Septic shock was the strongest predictor of AKI in our
cohort. Many authors agree that the renal effects of sep-
sis, per se, should not be underestimated. Early AKI is
common in septic shock [32], and it may potentiate the
effects of colistin and other drugs on the kidney. The
combination of septic shock and AKI had a consistently
negative effect on survival. Among the patients with
septic shock who did not receive CMS at all (that is,
those who were treated with NAs alone), the incidence
of AKI was 64% (45/70), which confirms the predomi-
nant role of septic shock in the kidney injury (Figure 1).
Limitation of the study
The main limitation of our study is its retrospective
design. This shortcoming is partially compensated for by
the large number of patients studied, but it is almost
impossible to avoid. A prospective randomized trial would
inevitably be associated with ethical problems since for
many infections, colistin is the only treatment option.
None of the patients received the CMS as empirical
therapy and a definitive appropriate therapy was
achieved within 36/48 hours. There are no data showing
that using CMS as an empiric regimen could reduce the
risk of inappropriate therapy and/or could reduce the
incidence of septic shock or increase the risk of AKI.
These interesting issues should be tested by specific
trials.
Conclusions
In conclusion, in ICU patients with normal baseline
renal function who receive CMS and/or NAs, the inci-
dence of AKI as defined by the RIFLE classification is
clearly high - 40%. However, high-dose CMS therapy
does not appear to be a risk factor for this outcome.
Instead, the development of AKI was strongly correlated
with the presence of septic shock and with the severity
of the patients’ underlying illness, as reflected by the
SAPS II score. These findings suggest that renal protec-
tion measures, such as blood volume maintenance, are
of utmost importance in critically ill patients with infec-
tions that require treatment with CMS.
Key messages
• The incidence of AKI in critically ill patients without
pre-existing renal diseases is strongly correlated with the
presence of septic shock and with illness severity.
• Compared with other nephrotoxic antimicrobials,
high-dose CMS does not appear to increase the risk of
new-onset AKI in this setting.
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